Sign In
Buy NEPH
Nephros Earnings Calls
| Release date | Nov 06, 2025 |
| EPS estimate | $0.0100 |
| EPS actual | $0.0300 |
| EPS Surprise | 200.00% |
| Revenue estimate | 4.451M |
| Revenue actual | 4.764M |
| Revenue Surprise | 7.03% |
| Release date | Aug 07, 2025 |
| EPS estimate | -$0.0250 |
| EPS actual | $0.0200 |
| EPS Surprise | 180.00% |
| Revenue estimate | 3.601M |
| Revenue actual | 4.419M |
| Revenue Surprise | 22.72% |
| Release date | May 15, 2025 |
| EPS estimate | $0.0100 |
| EPS actual | $0.0500 |
| EPS Surprise | 400.00% |
| Revenue estimate | 3.621M |
| Revenue actual | 4.877M |
| Revenue Surprise | 34.69% |
| Release date | Mar 24, 2025 |
| EPS estimate | -$0.0100 |
| EPS actual | $0.0300 |
| EPS Surprise | 400.00% |
| Revenue estimate | 3.672M |
| Revenue actual | 3.87M |
| Revenue Surprise | 5.41% |
Last 4 Quarters for Nephros
Below you can see how NEPH performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Mar 24, 2025 |
| Price on release | $1.52 |
| EPS estimate | -$0.0100 |
| EPS actual | $0.0300 |
| EPS surprise | 400.00% |
| Date | Price |
|---|---|
| Mar 18, 2025 | $1.52 |
| Mar 19, 2025 | $1.49 |
| Mar 20, 2025 | $1.50 |
| Mar 21, 2025 | $1.55 |
| Mar 24, 2025 | $1.52 |
| Mar 25, 2025 | $1.54 |
| Mar 26, 2025 | $1.60 |
| Mar 27, 2025 | $1.67 |
| Mar 28, 2025 | $1.67 |
| 4 days before | 0% |
| 4 days after | 9.87% |
| On release day | 1.32% |
| Change in period | 9.87% |
| Release date | May 15, 2025 |
| Price on release | $2.14 |
| EPS estimate | $0.0100 |
| EPS actual | $0.0500 |
| EPS surprise | 400.00% |
| Date | Price |
|---|---|
| May 09, 2025 | $1.90 |
| May 12, 2025 | $2.07 |
| May 13, 2025 | $2.17 |
| May 14, 2025 | $2.09 |
| May 15, 2025 | $2.14 |
| May 16, 2025 | $2.16 |
| May 19, 2025 | $2.15 |
| May 20, 2025 | $2.30 |
| May 21, 2025 | $2.26 |
| 4 days before | 12.63% |
| 4 days after | 5.61% |
| On release day | 0.93% |
| Change in period | 18.95% |
| Release date | Aug 07, 2025 |
| Price on release | $2.89 |
| EPS estimate | -$0.0250 |
| EPS actual | $0.0200 |
| EPS surprise | 180.00% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $3.42 |
| Aug 04, 2025 | $3.24 |
| Aug 05, 2025 | $3.10 |
| Aug 06, 2025 | $3.00 |
| Aug 07, 2025 | $2.89 |
| Aug 08, 2025 | $3.90 |
| Aug 11, 2025 | $4.49 |
| Aug 12, 2025 | $4.26 |
| Aug 13, 2025 | $4.12 |
| 4 days before | -15.50% |
| 4 days after | 42.56% |
| On release day | 34.95% |
| Change in period | 20.47% |
| Release date | Nov 06, 2025 |
| Price on release | $5.20 |
| EPS estimate | $0.0100 |
| EPS actual | $0.0300 |
| EPS surprise | 200.00% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $5.70 |
| Nov 03, 2025 | $5.37 |
| Nov 04, 2025 | $5.40 |
| Nov 05, 2025 | $5.69 |
| Nov 06, 2025 | $5.20 |
| Nov 07, 2025 | $4.60 |
| Nov 10, 2025 | $4.29 |
| Nov 11, 2025 | $4.33 |
| Nov 12, 2025 | $4.56 |
| 4 days before | -8.77% |
| 4 days after | -12.31% |
| On release day | -11.54% |
| Change in period | -20.00% |
Nephros Earnings Call Transcript Summary of Q3 2025
Nephros reported strong third quarter 2025 results highlighted by $4.8 million in revenue (up 35% year-over-year), the company’s second-highest quarterly revenue, and its fifth consecutive profitable quarter. Programmatic (recurring) business reached a record high, driven by an expansion of the filtration installation program and higher service revenue. Gross margins remained healthy (~61% for the quarter; ~63% year-to-date) despite some inventory/tariff pressures. Adjusted EBITDA was positive ($418k Q3; $1.4M year-to-date), net income improved ($337k Q3; $1.1M year-to-date), operating cash flows turned positive, cash increased to $5.2M as of September 30, 2025, and the company remains debt-free. Management highlighted new product rollouts — notably a PFAS removal solution now in the field — and an active innovation pipeline targeting PFAS, microplastics and nanoplastics. The company is pursuing both direct and distributor channels, expanding into non-hospital verticals (municipalities, labs, dental, aviation, government buildings), and sees installation and a tracking app as important drivers for customer retention and upsell. Management emphasized disciplined SG&A growth, targeted sales additions, and continued focus on education and water-safety program leadership as the path to sustained growth.
